Clinical trials: Liver Tumour
Hepatocellular Carcinoma, Liver Carcinoma
the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma
This study aimed to evaluate whether nutritional optimization-led triple prehabilitation could improve perioperative nutritional status, promote postoperative recovery, and reduce postoperative complications in patients with…
- Conditions
- Hepatocellular Carcinoma, Liver Carcinoma, Hepatobiliary Cancers, Primary Liver Cancer
- Trial name
- NCT06549829
- Testing
- Nutritional optimization-led triple prehabilitation Intervention, Conventional triple prehabilitation Intervention
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
This retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving…
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI), Tyrosine Kinase Inhibitors
- Trial name
- NCT07449065
- Testing
- TKI, TACE
- Where
- China
- Volunteers
- 324 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Liver Transplant; Complications, Cirrhosis, Liver
Prehabilitation and Posttransplant Training Program in Liver Transplantation
PreLiveR-T consists of a prospective randomized clinical trial conducted in an adult population that is a candidate for liver transplantation (LT) at the Hospital La Fe Valencia (Spain).
- Conditions
- Liver Transplant; Complications, Cirrhosis, Liver, Hepatic Carcinoma
- Trial name
- PreLiveR-T (NCT04246970)
- Testing
- Prehabilitation, Prehabilitation and posttransplant training program
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Maria dels Angels Cebria i Iranzo, PT, PhD
Advanced Breast Cancer, Advanced Liver Cancer
Plasmodium Immunotherapy for Breast and Liver Cancers
The purpose of this study is to evaluate the safety and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced breast cancers and advanced liver cancers.The treatment will last 4-6 weeks from the day of…
- Trial name
- NCT03474822
- Testing
- Blood-stage infection of P.vivax
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
Carcinoma, Hepatocellular
PI-88 in Hepatocellular Carcinoma After Hepatectomy
The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.
- Trial name
- NCT00247728
- Testing
- PI-88
- Where
- 6 sites in Taiwan
- Volunteers
- 172 people
- Sponsor
- Cellxpert Biotechnology Corp.
Sarcoma, Cervical Cancer
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
The present trial is an open, single-arm phase I clinical study aimed at assessing the safety, tolerability, viral distribution and shedding patterns, pharmacodynamics, immunogenicity, and antitumor efficacy of GC001 oncolytic…
- Conditions
- Sarcoma, Cervical Cancer, Colon Cancer, Lung Cancer
- Trial name
- NCT06508307
- Testing
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors
- Where
- China
- Volunteers
- 21 people
- Sponsor
- GONGCHU Biotechnology Co., Ltd
Hemostasis in Decompensated Liver Cirrhosis, Inflammation in Decompensated Liver Cirrhosis
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
- Trial name
- HELICS (NCT06212635)
- Testing
- T-TAS
- Where
- Sweden
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Region Stockholm
Carcinoma, Hepatocellular
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.
- Trial name
- NCT00635323
- Testing
- Irinotecan plus capecitabine
- Where
- 9 sites in China, Hong Kong and 2 more
- Volunteers
- 73 people
- Sponsor
- Pfizer
Focal Nodular Hyperplasia of Liver, Toxic Liver Disease With Focal Nodular Hyperplasia
Contrast Enhanced Ultrasound For The Evaluation Of Focal Liver Lesions
The aim of the study is to assess the value of contrast enhanced ultrasound in the evaluation of de novo focal liver lesions in clinical practice, in a prospective multi-center design.
- Conditions
- Focal Nodular Hyperplasia of Liver, Toxic Liver Disease With Focal Nodular Hyperplasia, Liver Metastases
- Trial name
- HepFocUS (NCT01329458)
- Where
- 5 sites in Romania
- Volunteers
- 1,500 people
- Sponsor
- Societatea Romana de Ultrasonografie in Medicina si Biologie
Pancreatitis, Pancreatic Neoplasms
Follow-up Study of Complications of Acute Pancreatitis
This is a follow-up study focusing on long-term complications of acute pancreatitis. The primary purposes include: 1. To assess the incidence of type 2 diabetes mellitus（2-DM）,impaired glucose tolerance, metabolic abnormalities…
- Conditions
- Pancreatitis, Pancreatic Neoplasms, Metabolic Diseases, Hypertension, Portal
- Trial name
- FSCAP (NCT02305914)
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Hepatocellular Carcinoma
A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC
This retrospective, multinational, single-arm study will be conducted in at least 8 sites. An interim analysis will be conducted with data from 100 patients with up to 10 well defined HCC tumor(s) and with at least one tumor ≥3…
- Trial name
- TARGET (NCT03295006)
- Testing
- TheraSphere
- Where
- 14 sites in United States, France and 6 more
- Volunteers
- 209 people
- Sponsor
- Boston Scientific Corporation
Liver Cancer
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020774
- Testing
- gemcitabine hydrochloride, lonafarnib, conventional surgery
- Sponsor
- Jonsson Comprehensive Cancer Center
Sarcoma, Carcinoma
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
- Conditions
- Sarcoma, Carcinoma, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT05860374
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Hepatocellular Carcinoma
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
TACE(transcatheter arterial chemoembolization) has been recommended by domestic and international guidelines as the standard treatment for a subset of HCC patients with very high heterogeneity, including BCLC stage…
- Trial name
- NCT05220020
- Testing
- TACE(Transcatheter arterial chemoembolization), Lenvatinib
- Where
- China
- Volunteers
- 299 people
- Sponsor
- Sun Yat-sen University
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Liver Neoplasms
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
The purpose of this study is to demonstrate the Sensitivity and Specificity of SonoVue®-enhanced ultrasound is superior to that of unenhanced ultrasound for the characterization of benign versus malignant FLLs using final…
- Trial name
- NCT00829413
- Testing
- SonoVue®
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Bracco Diagnostics, Inc
Hepatocellular Carcinoma
Effects of Telephone Consultations on Discharged Liver Cancer
The aims of this three-year study are to: 1. From patients and family perspective to explore the needs for home care after receiving TACE, PEI, and RFA 2.
- Trial name
- NCT01595243
- Testing
- telephone consultations about psychoeducation program
- Where
- Taiwan
- Volunteers
- 254 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma (HCC)
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
This is an open-label, single-center, single-arm phase Ib clinical trial. The aim of this study is to assess the safety and efficacy of JS014 in combination with Toripalimab and transarterial chemoembolization (TACE) for…
- Trial name
- NCT06882876
- Testing
- JS014 Combined With Toripalimab and TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatocellular Carcinoma
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in patients with advanced hepatocellular…
- Trial name
- NCT04044313
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shi Ming
Hepatocellular Carcinoma
Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma
The primary goal of this study is to gather efficacy data concerning overall survival with electromagnetic field when compared to a placebo amplitude-modulated radiofrequency electromagnetic field device in subjects who have…
- Trial name
- TheraBionics (NCT04526080)
- Testing
- TheraBionic Device
- Where
- 3 sites in United States
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.